Intrinsic Factor Antibodies IFAB

Synonyms

Allscripts (AEHR) Order Name

Intrinsic Factor Blocking Antibody

Sunrise Clinical Manager (SCM) Order Name

Intrinsic Factor Blocking Antibody

EPIC Order Name

Intrinsic Factor Blocking Antibodies

Clinical Info

Intrinsic factor is a glycoprotein (produced by the parietal cells of the stomach) that is required for the absorption of vitamin B12 from the diet.1 During digestion, stomach acids dissociate B12 from food and intrinsic factor binds to it and allows it to be absorbed in the small intestine. Conditions that impair intrinsic factor production lead to B12 malabsorption and deficiency. Laboratory findings for B12 deficiency include decreased serum B12 levels, increased methylmalonic acid and megaloblastic anemia.2-6 Impaired hemoglobin synthesis associated with B12 deficiency is characterized by abnormal maturation of erythrocyte precursors in the bone marrow, which results in the presence of megaloblasts with hypersegmented neutrophils and decreased erythrocyte survival.4 Vitamin B12 deficiency is also associated with neurological abnormalities.5,6
A leading cause of vitamin B12 deficiency is pernicious anemia (PA) caused by intrinsic factor deficiency.7-10 The condition is referred to as "pernicious" because it is clinically silent initially and only becomes manifest when patients experience generalized symptoms, such as weakness, diminished energy and (less commonly) dyspepsia.9,11 The incidence of PA increases with age and is relatively rare in individuals younger than 30 years of age.10 The highest prevalence is seen in Northern Europeans, although PA has been reported in virtually every ethnic group.10 PA can be caused by pathologic conditions that damage or remove a portion
of the stomach's parietal cells, including bariatric surgery, gastric tumors, gastric ulcers, and excessive consumption of alcohol. Autoimmune ABG is caused by CD4 T cell-mediated autoimmune response directed against the gastric H/K-ATPase.11 Diagnosis of autoimmune PA relies on histologically proven atrophic body gastritis, megaloblastic anemia, B12 deficiency, and antibodies to intrinsic factor and to gastric parietal cells.10
Antiparietal cell antibodies are found in 90% of patients with PA, but have low specificity and are seen in atrophic gastritis without megaloblastic anemia as well as in various autoimmune disorders.10 Anti-intrinsic factor antibodies are less sensitive, being found in only 60% of patients with PA, but they are considered highly specific for PA.9,11-13 Laboratory diagnosis is further supported by increased levels of fasting gastrin and decreased levels of pepsinogen I.7,9
Epidemiological evidence and genetic studies suggest that PA has a significant heritable component and leucocyte antigen-DR genotypes suggest a role for genetic susceptibility.9,13,14 Long-standing Helicobacter pylori infection may play a predisposing role in many patients in whom the active infectious process has been gradually supplanted by an autoimmune disease that terminates in a burned-out infection and the irreversible destruction of the gastric body mucosa.9 PA is frequently associated with autoimmune thyroid disease (40%) and other autoimmune disorders, such as diabetes mellitus (10%), as part of the autoimmunepolyendocrine syndrome.8,9 PA incidence is also increased in patients with primary biliary cirrhosis compared to controls.15 Autoimmune gastritis may predispose to gastric carcinoid tumors or adenocarcinomas.
 

Specimen Type

Blood

Specimen Volume

2 mL serum (1 mL min)

Container

Gold Top Tube

Collection Instructions

Container/Tube: Gold Top Tube
Specimen: 2 mL serum (1 mL min)
Transport Temperature: Refrigerated
Stability: 14 Days Room Temperature, Refrigerated, Frozen
Patient Preparation
No specimen should be collected from a patient currently undergoing B12 therapy less than one week after the last B12 injection.

Transport Instructions

Refrigerated

Specimen Stability

14 Days Room Temperature, Refrigerated, Frozen
Patient Preparation
No specimen should be collected from a patient currently undergoing B12 therapy less than one week after the last B12 injection.

Methodology

Immunochemiluminometric assay (ICMA)

Days Performed

Performing Laboratories

LabCorp

CPT

86340
 
LOINC Code: 31443-5

PDM

5900870

Result Interpretation

Forms